APRETUDE

DRUG2 trials

Sponsors

ViiV Healthcare

Conditions

HIV Infections

Phase 4

A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States

CompletedNCT05374525

ViiV HealthcareHIV Infections

Start: 2022-05-18End: 2024-08-08Updated: 2025-12-15

A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories

CompletedNCT05514509

ViiV HealthcareHIV Infections

Start: 2022-10-28End: 2025-09-02Updated: 2026-02-09

Related Papers

Implementation Journey with CAB LA for PrEP Among Men Who Have Sex with Men and Transgender Men: Insights from the PILLAR Trial Through 12 Months

AIDS and Behavior2026-07-12

Strategies for implementing long‐acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study

Journal of the International AIDS Society2025-07-011 citations

P-1899. Improvement in Provider Experiences from Baseline to Month 12 with Integrating Cabotegravir Long-Acting (CAB LA) for PrEP into Care in an Implementation Science Trial (PILLAR)

Open Forum Infectious Diseases2025-01-29